To clarify whether plasma somatostatin affects thyrotropin secretion in critical illness, plasma somatostatin and thyrotropin responses to thyrotropin-releasing hormone were studied in forty-three critically ill patients. High somatostatin levels were associated with blunted thyrotropin secretion in critically ill patients. There was an inverse correlation between plasma somatostatin levels and the maximum increment of thyrotropin after stimulation by thyrotropin-releasing hormone. Decreased somatostatin and increased thyrotropin secretion before discharge from the intensive care unit were demonstrated in survivors. On the other hand, non-survivors maintained high somatostatin levels and had blunted thyrotropin secretion during their intensive care admission. These results suggest that high plasma somatostatin levels may play a role in the blunted thyrotropin secretion observed in critical illness.
A low thyrotropin level and blunted thyrotropin response to thyrotropin-releasing hormone (TRH) is often observed in critically ill patients [1] [2] [3] [4] . Although various factors affect thyrotropin secretion, such as dopamine medication 5, 6 , exogenous steroids 7 , interleukin-1 8 and tumor necrosis factor 9,10 , the mechanism of thyrotropin suppression remains to be elucidated.
Somatostatin, one of the hypothalamic hormones, has been shown to suppress both basal thyrotropin and thyrotropin response to TRH, and it may play a physiological role in thyrotropin secretion 11, 12 . Although peripherally circulating somatostatin consists of somatostatin-14 (S-14), mainly secreted from the central nervous system, and somatostatin-28 (S-28), mainly secreted from the gastrointestinal tract [13] [14] [15] , both have an equally suppressive effect on pituitary hormone secretion 16 . However, there is little information about the relationship between plasma somatostatin levels and the suppression of thyrotropin secretion in critically ill patients. The purpose of this study was to measure plasma somatostatin and thyrotropin secretion in critically ill patients without known thyroid disease, and to investigate the correlation between plasma somatostatin and thyrotropin secretion stimulated by TRH.
PATIENTS AND METHODS
This study was approved by the Hospital Ethics Committee for Research on Human Subjects in our institution. Informed consent was obtained from the patients, where possible, or otherwise from the next of kin.
Patients and Sampling. For this study, we selected critically ill patients without known thyroid disease with a clinical diagnosis of multiple organ failure (MOF) who had been admitted to the intensive care unit (ICU). MOF was diagnosed by the criteria of Goris et al 17 based on the data obtained within the first 24 hours of ICU admission. The study was completed on forty-three patients, twenty-nine males aged 21 to 77 years and fourteen females aged 22 to 77 years. Survival was defined as survival to the time of hospital discharge. Dopamine medication and enteral nutritional support at the time of hormone tests, and exogenous steroid dosage within the week before ICU admission were documented. Clinical diagnoses of patients are shown in Table 1 .
Acute Physiology and Chronic Health Evaluation (APACHE) II score 18 and organ failure score 17 were determined for all patients based on physiologic variables obtained within 24 hours of ICU admission. Blood samples for leukocyte counts and creatinine were taken on admission. The thyrotropin and prolactin responses to TRH were tested within 24 hours of ICU admission. A basal sample was drawn from an artery just prior to 10 a.m. for determinations of somatostatin, thyrotropin and prolactin levels, followed by stimulation with 500 µg of synthetic TRH (protiretin) administered intravenously at 10 a.m. After 15, 30, 60, 90 and 120 minutes, additional blood samples were drawn to determine thyrotropin and prolactin levels. Hormone variables and severity of patients at ICU admission are shown in Table 2 .
Thirteen patients, five survivors and eight nonsurvivors, had the same battery of hormone tests within 48 hours before ICU discharge while their mean arterial pressure was maintained at more than 80 mmHg. To measure somatostatin levels of jugular bulb blood, a catheter was inserted upward from the internal jugular vein and the tip of catheter was placed in the jugular bulb in seven patients. Their levels were compared with arterial blood sampling in each patient.
Hormone Assay. For the somatostatin measurements, blood samples were immediately placed in chilled heparinized tubes containing 500 kallikrein inhibitory units of aprotinin (Trasylol, Bayer) and 12 mg EDTA per ml of blood. The samples were then centrifuged, and the plasma was aliquotted. All aliquots were stored at -30°C until the relevant estimations were done. Somatostatin was measured by a radioimmunoassay. Briefly, rabbit (New Zealand White) anti-somatostatin-14 (S-14)-serum (OAL-202), [ 125 I]-Nα-Tyr 1 -somatostatin as a tracer, and synthetic somatostatin-14 (S-14) as a standard were incubated for 72 hours in a 0.2 ml volume of 55 mM ammonium acetate buffer at pH 5.3. Separation of antibody-bound from free labelled somatostatin was achieved using 0.5 ml of dextran-coated charcoal solution. The sensitivity of the assay is 31.5 pg/ml of plasma, the intra-assay and inter-assay coefficients of variation are 5.2% and 7.3%, respectively. Normal fasting plasma somatostatin levels are 60.5±20.0 pg/ml (healthy adult subjects n=20, mean±SD). This assay showed 43% cross reactivity with synthetic somatostatin-28 (S-28).
Thyrotropin was measured with a radioimmunoassay kit by Behring-Werke (Hoechst, Germany). Normal thyrotropin level is 0.1 to 4.0 µIU/ml and normal peak thyrotropin level after stimulation by TRH ranges from 10.0 to 30.0 µIU/ml.
Prolactin was measured with a radioimmunoassay kit by Daiichi Radioisotope (Tokyo, Japan). Normal prolactin level is below 30.0 ng/ml and peak prolactin level after stimulation by TRH is twice as high as basal prolactin level (manufacturer's data).
Statistical Analysis. Statistics were calculated using a software program (Stat View 4.02, Abacus Concepts, Berkeley, CA). Data were not normally distributed, and are therefore presented as a median value and interquartile range. To test for differences between groups, the Mann-Whitney U test, and for changes in variables in groups, the Wilcoxon signedrank test were used. Categorical data were analysed by the chi-square test. Spearman's correlation coefficients were calculated to investigate possible relationships between somatostatin levels and thyrotropin secretion and prolactin secretion. Statistical significance was indicated by P<0.05.
RESULTS
The clinical characteristics of patients are presented in Table 2 . Of the 43 study subjects, 24 (56%) died (nonsurvivors) and the other 19 (44%) survived until hospital discharge (survivors). Dopamine was administered when needed to maintain the mean arterial pressure at more than 80 mmHg. Corticosteroids were used in eight patients during the week before ICU admission. Nineteen patients were supported by total or partial enteral feeding simultaneously with parenteral nutrition and the other patients were supported by total parenteral nutrition at the time of hormone tests at ICU admission. The survivors and nonsurvivors were similar in terms of sex, age and the frequencies of corticosteroid usage, dopamine-medication and enteral feeding at ICU admission. At the time of the hormone tests before ICU discharge, all of the survivors were receiving enteral feeding whilst all of the nonsurvivors were receiving total parenteral nutrition without enteral feeding. Severity scores (APACHE II score and organ failure score) of nonsurvivors were significantly higher than those of survivors ( Table 2 ).
Somatostatin levels were increased above normal fasting levels in critically ill patients, with a median value of 124.8 (90.9-147.5) pg/ml. Nonsurvivors showed significantly higher somatostatin levels than survivors (Table 3 ). Somatostatin levels in the patients with enteral feeding (n=19) and without enteral feeding (n=24) were 139.0 (94.9-159.8) and 115.6 (90.3-142.2) pg/ml (P=0.20), respectively. Jugular bulb blood and arterial somatostatin levels in those patients were 100.2 (81.3-125.6) and 97.2 (92.7-101.5) pg/ml (P=0.88), respectively. Both basal thyrotropin levels and peak thyrotropin levels after stimulation by TRH within 24 hours of ICU admission were significantly higher in survivors than in nonsurvivors (Table 3 ). Only two survivors achieved a normal peak thyrotropin level (4.6%) and all the nonsurvivors showed blunted thyrotropin responses. Neither basal nor peak thyrotropin levels showed statistical significances by dopa-mine medication. Basal thyrotropin levels were 0.18 (0.10-0.36) µIU/ml in the group with dopamine medication and 0.79 (0.16-1.63) µIU/ml in the group without dopamine medication (P=0.06). Peak thyrotropin levels were 1.25 (0.43-3.08) µIU/ml in the group with dopamine medication and 2.92 (1.51-6.23) µIU/ml in the group without dopamine medication (P=0. 12) .
No significant differences between survivors and nonsurvivors in basal and peak prolactin levels were demonstrated. Peak prolactin levels of both survivors and nonsurvivors increased significantly compared with basal prolactin levels.
Survivors showed a significant increase in maximum increments of thyrotropin secretion after the stimulation by TRH (∆ thyrotropin), and significant decreases in somatostatin levels, APACHE II score and organ failure score before ICU discharge. On the contrary, nonsurvivors showed a significant decrease in ∆ thyrotropin and increases in somatostatin levels, APACHE II score and organ failure score (Figure 1) .
Somatostatin levels correlated significantly with thyrotropin secretion including ∆ thyrotropin (rs= -0.611, P<.0001, Figure 2 ), basal thyrotropin levels (r s =-0.37, P=0.006) and peak thyrotropin levels (rs= -0.58, P<0.0001), but not with prolactin secretion.
DISCUSSION
The main findings of this study were that a high somatostatin level was associated with suppression of thyrotropin secretion, and it significantly inversely correlated with thyrotropin secretion after stimulation by TRH in critically ill patients. Survivors increased thyrotropin secretion and decreased somatostatin levels before ICU discharge, but nonsurvivors kept the suppression of thyrotropin secretion and high somatostatin levels before ICU discharge. These results demonstrate that high peripheral somatostatin levels may be the cause of the blunted thyrotropin secretion seen in critically ill patients.
The suppressive effects of somatostatin on basal thyrotropin levels and on thyrotropin release by TRH have been induced by somatostatin administration in normal men 11, 12 . Sufficient amounts of somatostatin antiserum injection into rats caused increases in thyrotropin levels, probably due to the neutralization of endogenous somatostatin in the portal blood 19 . On the other hand, prolactin release by TRH was not inhibited by somatostatin administration 12 . These results suggest that an increased plasma somatostatin level may induce the suppression of thyrotropin secretion without affecting prolactin secretion. In the present study, critically ill patients showed suppres- Peak thyrotropin: peak thyrotropin level after stimulating by thyrotropin-releasing hormone (TRH); peak prolactin: peak prolactin level after TRH; ns: not significant; a:Mann-Whitney U test. sion of thyrotropin secretion after stimulation by TRH while they had normal prolactin secretion. This pattern is similar to the observed response of these hormones to somatostatin administration in normal subjects.
The origin of the high somatostatin concentrations observed in this study remains unclear. It is difficult to assess both the role and the source of somatostatin detected in the peripheral blood, since this hormone is distributed throughout the central nervous system and in many tissues outside the brain including the gut and endocrine and exocrine glands 14, 15 . Saito et al 20 reported plasma somatostatin levels in various diseases. Of 86 patients, nine showed elevated somatostatin levels. Five of these were diagnosed as having a somatostatin secreting tumor, but the reasons for high somatostatin levels in the other four patients were not mentioned. Several investigations have shown that a meal increases peripheral somatostatin levels [21] [22] [23] [24] . Most of the increased somatostatin consisted of somatostatin-28 (S-28) which is mainly secreted from the pancreas and/or the gastrointestinal tract [13] [14] [15] . Since the ability of S-28 to inhibit the release of pituitary hormones is equal to or larger than anti-somatostation (S-14) 16 , peripheral somatostatin including both S-14 and S-28, may affect thyrotropin secretion. Although anti-somatostatin (S-14)-serum (OAL-202) used for radioimmunoassay in this study, had cross-reactivity with S-28, there were no significant differences in somatostatin levels between the patients with enteral feeding and those without. Moreover survivors had decreased somatostatin levels before ICU discharge in spite of having had enteral feeding at the time of hormone tests, and nonsurvivors increased those levels despite having no enteral feeding before ICU discharge. These results indicate that enteral feeding is unlikely to be the cause of the increased peripheral somatostatin levels in critically ill patients.
In summary, increased plasma somatostatin levels and blunted thyrotropin secretion were observed simultaneously in critically ill patients. Somatostatin levels inversely correlated with ∆ thyrotropin. These results suggest that the high somatostatin levels might affect suppression of thyrotropin secretion. Somatostatin may play a pathophysiological role in the suppression of thyrotropin secretion observed in critical illness.
